Last reviewed · How we verify
Iopamidol 300 (Contrast)
Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.
Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.
At a glance
| Generic name | Iopamidol 300 (Contrast) |
|---|---|
| Sponsor | University of Michigan |
| Drug class | Non-ionic iodinated contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It is administered intravenously and distributes throughout the vascular system and extracellular space, allowing enhanced visualization of blood vessels, organs, and tissues during angiography, CT, and other imaging procedures. The non-ionic formulation reduces osmolality compared to ionic agents, lowering the risk of adverse reactions.
Approved indications
- Contrast enhancement for angiography and vascular imaging
- Contrast enhancement for computed tomography (CT) imaging
- Contrast enhancement for urography and other radiographic procedures
Common side effects
- Contrast-induced nephropathy
- Allergic reaction (mild to severe)
- Nausea and vomiting
- Flushing and warmth sensation
- Hypersensitivity reactions
Key clinical trials
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (PHASE1)
- ISOVUE Comparative Trial (NA)
- Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain (PHASE4)
- CT-guided Ablation of the Ganglion Impar for Pelvic Tumors: Comparethe Addition of Ketorolac or Dexamethasone (NA)
- Customized Contrast Media Dose Clinical Trial (NA)
- Double-Blind Placebo-Controlled CIN Trial (PHASE4)
- Thoracoabdominal Arortic CTA Study (PHASE4)
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopamidol 300 (Contrast) CI brief — competitive landscape report
- Iopamidol 300 (Contrast) updates RSS · CI watch RSS
- University of Michigan portfolio CI